Highest-materiality recent filing
PURE Bioscience reports Q3 net loss of $624k; CEO Bartlett to retire July 31, Kitchell to succeed
Q3 net product sales $506k (+3.5% YoY); net loss $624k vs $580k YoY; EPS ($0.01).
Pure Bioscience raises $1.0M in private placement at $0.0553/share; directors invest
Closed private placement of 18,131,096 shares at $0.0553/share for $1.0M gross.
PURE Bioscience Q2 revenue up 13% to $443K; net loss narrows; USDA cert for PURE Clean
Net product sales Q2 $443K (up 13% YoY); six-month sales $1.15M (up 22% YoY).
Pure Bioscience shareholders approve increase in authorized shares to 250M
Approved amendment increasing authorized common shares from 200M to 250M, with 63.87% of outstanding shares voting for.
PURE Bioscience reports fiscal Q1 2026 revenue up 27% to $707K, net loss narrows to $464K
Net product sales $707K for Q1 ended Oct 31, 2025, up 27% from $555K YoY.
PURE Bioscience promotes Jeff Kitchell to President, Dolana Blount to VP of Operations
Jeffrey Kitchell appointed President and remains Corporate Secretary, effective Nov 17, 2025.
PURE Bioscience FY2025 net product sales $2.2M, net loss narrows to $2.4M from $3.4M
Net product sales $2,198K for FY2025, up 12.4% from $1,955K in FY2024.
PURE Bioscience Q3 net product sales up 11% YoY; net loss narrows to $580K
Net product sales $489K in fiscal Q3 ended Apr 30, 2025, up from $440K YoY.
PURE Bioscience Q2 net sales up 20% YoY to $391K; net loss narrows to $798K
Net product sales $391K for fiscal Q2 ended Jan 31, 2025, vs $325K a year ago (+20%).
Pure Bioscience Announces Results of 2025 Annual Meeting of Stockholders
Stockholders elected all seven director nominees with approval ranging from 95.59% to 98.18%.
PURE Bioscience Q1 FY2025 product sales $555K, down 23% YoY; net loss per share ($0.01)
Net product sales of $555K for quarter ended Oct 31, 2024, vs $718K YoY, due to budget constraints of a large end-use customer.
PURE Bioscience reports FY 2024 net loss of $3.4M; product sales up 4.5% to $1.955M
Net product sales $1.955M in FY 2024 vs $1.871M in FY 2023, up $84K (4.5%).
Pure Bioscience secures up to $3M in convertible notes; initial $500k from director Tom Y. Lee
Initial tranche of $500,000 convertible promissory note placed with director Tom Y. Lee (affiliates).
Pure Bioscience increases authorized common shares from 150M to 200M
Shareholders approved the amendment at the Feb 21, 2024 annual meeting.
PURE Bioscience Q3 net product sales $440K, net loss $857K; loss per share ($0.01)
Net product sales $440,000 for Q3 FY2024, up 8% vs $406,000 in prior-year quarter.
Pure Bioscience appoints Darin Zehr to board of directors, effective May 1, 2024
Darin Zehr appointed as independent director; will serve on Audit and Compensation Committees.
Pure Bioscience raises $500K via convertible notes from director; up to $3M total
Initial $500,000 private placement of convertible promissory notes to accredited investors, including board member Tom Y. Lee.
PURE Bioscience Q2 net product sales $325K, net loss $1.0M; shifting to distributor model
Net product sales $325K in Q2 FY2024, down 18% from $396K YoY; net loss $1.002M vs $1.060M.
Pure Bioscience shareholders approve increase in authorized shares to 200M
All six director nominees elected with 97-99% of votes cast; terms until next annual meeting.
PURE Bioscience Q1 revenue rises 54% to $718K; net loss narrows to $735K
Net product sales of $718K for Q1 FY2024, up $251K from $467K in Q1 FY2023.
PURE Bioscience reports FY2023 net loss of $4.0M, revenue up slightly; Q4 revenue jumps 49% YoY
Net product sales $1.871M vs $1.813M prior year (+3.2%); net loss widened to $4.0M from $3.5M.
Pure Bioscience raises $1.015M via convertible notes from accredited investors
Issued convertible promissory notes for $1.015M initial principal; potential subsequent closings up to $1.8M total.
PURE Bioscience Q3 net product sales down 18% YoY to $406K; net loss widens to $876K
Net product sales $406K in Q3 FY2023 vs $497K prior year, down 18% on decreased distribution sales.
Pure Bioscience names Robert Bartlett CEO; Tom Lee resigns, stays on Board
Tom Y. Lee resigned as President and CEO effective March 15, 2023; will continue on Board.
PURE Bioscience Q2 net loss widens to $1.06M; CEO Tom Y. Lee resigns, Robert Bartlett appointed
Q2 net product sales $396K, down ~4.6% YoY; net loss $1.06M vs $702K prior year.
All seven director nominees elected with between 96.60% and 99.19% of votes cast.
PURE Bioscience Q1 FY2023 net product sales $467K, net loss widens to $993K
Net product sales $467K, down 6% from $497K YoY; net loss $993K vs. $796K.
PURE Bioscience FY2022 revenue down 51% to $1.8M; net loss widens to $3.5M
Net product sales of $1.81M vs $3.70M in FY2021; royalties fell to $40K from $229K.
PURE Bioscience raises $3.5M in private placement; CEO and directors participate
Raised $3.5M via private placement of 23,333,332 shares at $0.15/share.
PURE Bioscience Q3 sales down 11% to $497K; nine-month sales fall 50%; net loss widens
Q3 net product sales $497K (-11% YoY); net loss $760K ($0.01 per share).
PURE Bioscience Q2 sales drop 52% to $415K, net loss $702K
Net product sales for Q2 ended Jan 31, 2022 fell 52% to $415K from $868K YoY.
Pure Bioscience annual meeting: all proposals approved by wide margins
Shareholder turnout 61.57% (53,613,132 of 87,072,963 shares outstanding).
PURE Bioscience Q1 revenue plunges 65% to $497k; net loss widens to $796k
Net product sales $497k, down 65% YoY; net loss $796k vs $180k; EPS $(0.01) vs $(0.00).
PURE Bioscience reports FY2021 net loss of $2.3M; product sales drop 47% YoY
Net product sales $3.698M, down 47% from $6.917M in FY2020.
Pure Bioscience appoints Ivan Chen as Board Chair, replacing Tom Lee
Ivan Chen, current non-employee director, appointed Board Chair effective August 19, 2021.
On May 1, 2024, the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”) authorized and appointed Darin Zehr, as a member of the Board.
the Board appointed Robert Bartlett, a member of the Board, as the Company’s President and Chief Executive Officer, effective as of the Effective Date.
Tom Myers, the Company’s Chief Operating Officer and member of the Board, resigned as the Company’s Chief Operating Officer in connection with his transition to the Company’s Executive Vice President, Technology and Development, each effective as of the Effective Date.
On March 19, 2023, Kristin A. Taylor delivered notice to the Board of her resignation from the Board, effective March 19, 2023.
Tom Y. Lee, the President, Chief Executive Officer and member of the Board of Directors (the “Board”) of Pure Bioscience, Inc. (the “Company”), resigned as the Company’s President and Chief Executive Officer, effective as of the Effective Date.
Max materiality 0.75 · Median 0.60 · Most common event earnings